A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients

The purpose of this study is to investigate the safety, tolerability, and preliminary efficacy of the combination treatment of hydroxyurea capsules and valproic acid capsules, or the combination treatment of 6-mercaptopurine tablets and valproic acid capsules in male and female patients aged 18 years or older with acute myeloid leukemia or high- risk myelodysplastic syndrome. The population to be studied is newly diagnosed AML patients who are considered unfit for standard induction chemotherapy, HR-MDS unfit/ineligible for standard treatment, and relapsed/refractory AML/HR-MDS patients who a

Trial Details

NCT ID
NCT06199557
Phase
PHASE1 / PHASE2
Sponsor
Haukeland University Hospital
Status
RECRUITING
Cancer Type
Acute Myeloid (AML) Leukemia
Interventions
  • Hydroxyurea, Hydroxycarbamide
  • Valproic acid
  • 6-Mercaptopurine (6-MP)
Locations (sample)
  • Bergen, Bergen, Norway|60.39299,5.32415

Key Eligibility Criteria

  • Participants are eligible for the study only if all of the following criteria apply:
  • o Female or male, age 18 years or older
  • Written informed consent
  • Patients with Newly diagnosed AML, as defined by ELN 2022 criteria, or relapsed/refractory AML who: - are unfit, defined as HCT-CI ≥ 3, or - in the…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Myeloid (AML) Leukemia Trials on Trialify →